The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kochetov A.G.

Tsentr kardiokhirurgii i tsentr urologii 3-go Tsentral'nogo voennogo klinicheskogo gospitalia im. A.A. Vishnevskogo MO RF, Moskovskaia oblast', Krasnogorsk

Lyang O.V.

Assotsiatsija spetsialistov i organizatsij laboratornoj sluzhby «Federatsija laboratornoj meditsiny», 127083 Moskva, ul. 8 Marta, 1, str.12

Gimadiev R.R.

Russian Cardiology Research and Production Complex of the Ministry of Healthcare of the Russian Federation

Abramov A.A.

National Cardiology Research Center, Russian Ministry of Health, 3 Cherepkovskaya 15A, Moscow, 121552, Russian Federation

Zhirov I.V.

National medical research center of cardiology MH RF

Skvortsov A.A.

Federal State Budget Organization National Medical Research Center of Cardiology, Ministry of Healthcare Russian Federation, Moscow, Russia

Zaseeva A.V.

Russian Cardiology Research and Production Complex of the Ministry of Healthcare of the Russian Federation

Bosykh E.G.

Russian Cardiology Research and Production Complex of the Ministry of Healthcare of the Russian Federation

Masenko V.P.

National Medical Research Center of Cardiology, Ministry of Healthcare of Russia

Tereshchenko S.N.

National medical research center of cardiology MH RF

Assessment of circulating microRNA expression in patients with cardiovascular pathology

Authors:

Kochetov A.G., Lyang O.V., Gimadiev R.R., Abramov A.A., Zhirov I.V., Skvortsov A.A., Zaseeva A.V., Bosykh E.G., Masenko V.P., Tereshchenko S.N.

More about the authors

Journal: Laboratory Service. 2016;5(2): 28‑31

DOI: 10.17116/labs20165228-31

Views: 506

Downloaded: 7

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Kochetov AG, Lyang OV, Gimadiev RR, et al. . Assessment of circulating microRNA expression in patients with cardiovascular pathology. Laboratory Service. 2016;5(2):28‑31. (In Russ.)
https://doi.org/10.17116/labs20165228-31

МСФ на ЯМ
Close metadata
Recommended articles:
Diagnostic capa­bilities of circulating microRNA profiles in patients with acute coro­nary syndrome and stable coro­nary artery disease. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(2):125-132
Regu­latory miRNA21, miRNA92, miRNA221 and miRNAlet7 expression in caro­tid and coro­nary athe­rosclerotic plaques. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(3):245-252
Pecu­liarities of placental microRNA expression in patients with preeclampsia and fetal growth restriction. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):14-25

Numerous experimental and clinical research on cardiovascular diseases demonstrate dysregulation of circulating microRNA expression profiles. The goal of this study was to evaluate diagnostic potential of microRNA in plasma of patients with cardiovascular diseases (CVD) without evidence of chronic heart failure (CHF). Material and methods. The level of circulating microRNA (21, 423-5р, 208а, 499а and 34а) were tested in plasma of 15 patients with CVD without evidence of CHF and 29 apparently healthy people (control group) using real-time PCR. Results. Statistically significant differences of microRNA-423-5p and 21 levels in plasma of patients with CVD and control group were not found (р=0,785 and 0,407, respectively), and microRNA-208a and 499a were not detected in plasma. The level of microRNA-34a was increased by 10,4 i.u. in patients with CVD in comparison with the control group (p=0,016), threshold value 2,5 i.u., sensitivity and specificity — 87% and 72%, respectively. Among the patients with CVD the level of microRNA-34a was statistically increased by 9,5 i.u. in patients with ischemic heart disease: postinfarction cardiosclerosis in comparison with the control group (p=0,016), while statistically significant differences in patients with hypertensive disease in comparison with the control group were not found (p=0,16). Conclusion. The results of this study confirm the significance of microRNA-34a as potential biomarker of CVD with threshold value of risk of CVD development 2,5 i.u.

Keywords:

postinfarction cardiosclerosis
microRNA

Authors:

Kochetov A.G.

Tsentr kardiokhirurgii i tsentr urologii 3-go Tsentral'nogo voennogo klinicheskogo gospitalia im. A.A. Vishnevskogo MO RF, Moskovskaia oblast', Krasnogorsk

Lyang O.V.

Assotsiatsija spetsialistov i organizatsij laboratornoj sluzhby «Federatsija laboratornoj meditsiny», 127083 Moskva, ul. 8 Marta, 1, str.12

Gimadiev R.R.

Russian Cardiology Research and Production Complex of the Ministry of Healthcare of the Russian Federation

Abramov A.A.

National Cardiology Research Center, Russian Ministry of Health, 3 Cherepkovskaya 15A, Moscow, 121552, Russian Federation

Zhirov I.V.

National medical research center of cardiology MH RF

Skvortsov A.A.

Federal State Budget Organization National Medical Research Center of Cardiology, Ministry of Healthcare Russian Federation, Moscow, Russia

Zaseeva A.V.

Russian Cardiology Research and Production Complex of the Ministry of Healthcare of the Russian Federation

Bosykh E.G.

Russian Cardiology Research and Production Complex of the Ministry of Healthcare of the Russian Federation

Masenko V.P.

National Medical Research Center of Cardiology, Ministry of Healthcare of Russia

Tereshchenko S.N.

National medical research center of cardiology MH RF

List of references:

  1. Kochetov A, Zhirov I, Masenko V, Gimadiev R, Lyang O, Tereshchenko S. Prospects of use of microRNAs in the diagnostics and treatment of heart failure. Kardiologicheskii vestnik. 9(2):62-67. (In Russ.)
  2. Bartel B. MicroRNAs directing siRNA biogenesis. Nat Struct Mol Biol. 2005;12(7):569-571.  doi:10.1038/nsmb0705-569
  3. Tabuchi T, Satoh M, Itoh T, Nakamura M. MicroRNA-34a regulates the longevity-associated protein SIRT1 in coronary artery disease: effect of statins on SIRT1 and microRNA-34a expression. Clin Sci. 2012;123(3):161-171.  doi:10.1042/cs20110563
  4. Boon R, Iekushi K, Lechner S et al. MicroRNA-34a regulates cardiac ageing and function. Nature. 2013;495(7439):107-110.  doi:10.1038/nature11919
  5. Lv P, Zhou M, He J et al. Circulating miR-208b and miR-34a Are Associated with Left Ventricular Remodeling after Acute Myocardial Infarction. IJMS. 2014;15(4):5774-5788. doi:10.3390/ijms15045774
  6. Thum T, Gross C, Fiedler J et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008;456(7224):980-984.  doi:10.1038/nature07511
  7. Sheedy F, Palsson-McDermott E, Hennessy E et al. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nature Immunology. 2009;11(2):141-147.  doi:10.1038/ni.1828
  8. Zhang Q, Xiao Z, He F, Zou J, Wu S, Liu Z. MicroRNAs Regulate the Pathogenesis of CVB3-Induced Viral Myocarditis Intervirology. 2013;56(2):104-113.  doi:10.1159/000343750
  9. Sabatel C, Malvaux L, Bovy N et al. MicroRNA-21 exhibits antiangiogenic function by targeting RhoB expression in endothelial cells. PLoS ONE. 2011;6(2):e16979. doi:10.1371/journal.pone.0016979
  10. Tijsen A, Creemers E, Moerland P et al. MiR423-5p as a circulating biomarker for heart failure. Circulation Research. 2010;106(6):1035-1039. doi:10.1161/circresaha.110.218297
  11. Goren Y, Kushnir M, Zafrir B, Tabak S, Lewis B, Amir O. Serum levels of microRNAs in patients with heart failure. European Journal of Heart Failure. 2012;14(2):147-154.  doi:10.1093/eurjhf/hfr155
  12. Fan K, Zhang H, Shen J, Zhang Q, Li X. Circulating microRNAs levels in chinese heart failure patients caused by dilated cardiomyopathy. Indian Heart Journal. 2013;65(1):12-16.  doi:10.1016/j.ihj.2012.12.022
  13. van Rooij E, Sutherland L, Qi X, Richardson J, Hill J, Olson E. Control of stress-dependent cardiac growth and gene expression by a MicroRNA. Science. 2007;316(5824):575-579.  doi:10.1126/science.1139089
  14. Wang J, Jiao J, Li Q et al. miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1. Nature Medicine. 2010;17(1):71-78.  doi:10.1038/nm.2282
  15. Shieh J, Huang Y, Gilmore J, Srivastava D. Elevated miR-499 levels blunt the cardiac stress response. PLoS ONE. 2011;6(5):e19481. doi:10.1371/journal.pone.0019481
  16. D'Alessandra Y, Pompilio G, Capogrossi M. Letter by D'Alessandra et al. Regarding Article, «Circulating MicroRNA-208b and MicroRNA-499 Reflect Myocardial Damage in Cardiovascular Disease». Circulation: Cardiovascular Genetics. 2011;4(1):e7-e7.  doi:10.1161/circgenetics.110.958769

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.